References
1. Nidzworski D, Wasilewska E, Smietanka K, Szewczyk B,
Minta Z. Detection and differentiation of Newcastle disease
virus and influenza virus by using duplex real-time PCR, Acta
Biochim Pol. 2015; 260(3):475-80.
2. Alexander DJ. A review of avian influenza in different bird
species.Veterinary Microbiology. 2000; 74, 3-13.
3. Alexander DJ, Aldous EW, Fuller CM. The long view: a
selective review of 40 years of Newcastle disease research.
Avian Pathol. 2012; 41(4):329-35.
4. Alexandr, DJ, Senne DA. Newcastle disease and other avian
paramyxoviruses. L. D. Zavala,ed.Omnipress. 2008; 135-141.
5. Senne D.A., King D.J. & Kapczynski D.R. 2004. Control of
Newcastle disease by vaccinationDev Biol (Basel). 119:165-
70.
6. Assembly of Delegates of the OIE. Avian Influenza.
Paris,France: OIE; 2015
7. Hutchinson E, Fodor E. Purification of influenza virions by
haemadsorption and ultracentrifugation. Protocol Exchange.
2014; 2014: 10.1038.
8. Kalbfuss B, Wolff M, Morenweiser R, Reichl U. Purification
of cell culture-derived human influenza A virus by sizeexclusionand anion-exchange chromatography. Biotechnol
Bioeng. 2007; 96: 932–944.
9. Blanche F, Cameron B, Barbot A, et al. An improved anionexchange HPLC method for the detection and purification of
adenoviral particles. Gene Ther. 2000; 7: 1055–1062.
10. Guo P, El-Gohary Y, Prasadan K, et al. Rapid and
simplifiedpurification of recombinant adeno-associated virus. J
VirolMethods. 2012; 183: 139–146.
11. Heyward JT, Klimas RA, Stapp MD, Obijeski JF. The rapid,
concentration and purification of influenza virus from allantoic
fluid. Arch Virol. 1977; 55: 107–11911, 17.
12. Xiangpeng R, Chunyi X, Qingming K, Chengwen Z.
Proteomic analysis of purified Newcastle disease virus
particles. Proteome Science. 2012; 10:32.
13. McGinnes L.W., Pantua H., Reitter J., Morrison T.G.
Newcastle disease virus: propagation, quantification, and
storage. Curr. Protoc. Microbiol. 2006; Chapter 15 Unit
15F.12.
14. Ungerechts G., Bossow S., Leuchs B., Holm P.S.,
Rommelaere J., Coffey M., Coffin R., Bell J., Nettelbeck D.M.
Moving oncolytic viruses into the clinic: clinical-grade
production, purification, and characterization of diverse
oncolytic viruses. Mol. Ther. Methods Clin. Dev. 2016;
3:16018.
15. Vicente T., Mota J.P., Peixoto C., Alves P.M., Carrondo
M.J. Rational design and optimization of downstream
processes of virus particles for biopharmaceutical applications:
current advances. Biotechnol. Adv. 2011; 29:869–878.
16. Ebrahimi MM, Moghaddampour M, Tavassoli A,
Shahsavandi S. Vaccination of chicks with experimental
Newcastle disease and avian influenza oil-emulsion vaccines
by in ovo inoculation. Archives of Razi Institute. 2000; 51:
15–25.
17. Bradford MM. A rapid and sensitive method for the
quantitation of microgram quantities of protein utilizing the
principle of protein-dye binding. Anal Biochem 1976; 72:
248–254.
18. Allan WH, Gough RE. A standard hemagglutination
inhibition test for Newcastle disease.Vaccination and
challenge. Vet Rec. 1974; 95 (7):147-149.
19. Laemmli UK. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature. 1970; 227:
680–685.
20. Morenweiser R. Downstream processing of viral vectors
and vaccines, Gene Therapy. 2005; 12, S103–S110.
21. WHO Technical Report Series No. 927 (2005).
22. Mayo MA. A summary of taxonomic changes recently
approved by ICTV. Arch Virol. 2002 Aug; 147(8):1655-63.
doi: 10.1007/s007050200039.
23. Gallili GE, Ben-Nathan D. Newcastle disease vaccines.
Biotechnol Adv. 1998 Mar; 16(2):343-66. doi: 10.1016/s0734-
9750(97)00081-5.
24. Kramberger P, Urbas L, Štrancar A. Downstream
processing and chromatography based analytical methods for
production of vaccines, gene therapy vectors, and
bacteriophages. Human Vaccines & Immunotherapeutics.
2015; 11:4, 1010-1021.
25. Payal A, Lakhchaura BD, Grang SK. Evaluation of
immunogenic potential of 75 kDa and 56 kDa proteins of
Newcastle disease virus (NDV), Indian Journal of
Experimental Biology. 2010; 48, 889-895.
26. Reimer CB, Baker RS, van Frank RM, Newlin TE.
Purification of large quantities of influenza, virus by density
gradient centrifugation. J Virol. 1967; 1: 1207–1216.
27. DiNapoli JM, Yang L, Suguitan A Jr, Elankumaran S,
Dorward DW, Murphy BR, Samal SK, Collins PL, Bukreyev
A. Immunization of primates with a Newcastle disease virusvectored vaccine via the respiratory tract induces a high titer of
Nazari et al / Archives of Razi Institute, Vol. 79, No. 1 (2024) 109-117 117
serum neutralizing antibodies against highly pathogenic avian
influenza virus. J Virol. 2007 Nov; 81(21):11560-8.
28. Terrier O, Rolland JP, Rosa-Calatrava M, Lina B, Thomas
D, Moules V. Parainfluenza virus type 5 (PIV-5) morphology
revealed by cryo-electron microscopy. Virus Res. 2009 Jun;
142(1-2):200-3.
29. Goff PH, GAO Q, Palese P. A majority of infectious
Newcastle disease virus particles contain a single genome,
while a minority contain multiple genomes. J Virol. 2012 Oct;
86(19):10852-6.
30. Macpherson LW. Electron-Microscope Studies of the Virus
of Newcastle Disease. Can J Comp Med Vet Sci. 1956 Mar;
20(3):72-8.
31. Nazari shirvan A, Samianifar M, Ghodsian N. Purification
of avian influenza virus (H9N2) from allantoic fluid by sizeexclusion chromatography, Turk J Vet Anim Sci. 2016;
40:1506-8.
32. Loa CC, Lin TL, Wu CC, Bryan TA, Thacker HL, Hooper
T, et al. Purification of turkey coronavirus by Sephacryl sizeexclusion chromatography. J Virol Methods. 2002; 104: 187–
194.
33. Nayak DP, Lehmann S, Reichel U. Downstream processing
of MDCK cell-derived equine influenza virus. J Chromatogr
B. 2005; 823: 75–81.
34. Ernawati R, Ibrahim AL. Newcastle disease vaccination in
Malaysia: application of oil emulsion vaccine. Vet
Microbiol. 1995; 46(1-3):69-77.
35. Reed, L.J. Muench, H. (1938). A simple method of
estimating fifty percent endpoints. American Journal of
Hygiene 27:493-497.
)